Soft tissue sarcoma: An update on systemic treatment options for patients with advanced disease

Oncology Research and Treatment

Volumn 37, Issue 6, 2014, Pages 355-362

  Schöffski, Patrick ^a   Cornillie, Jasmien ^a   Wozniak, Agnieszka ^a   Li, Haifu ^a   Hompes, Daphne ^a  

^a Katholieke Universiteit   (Belgium)

Author keywords

Advanced disease; Chemotherapy; Metastasis; Soft tissue sarcoma; Targeted agents

Indexed keywords

CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; PALIFOSFAMIDE; PAZOPANIB; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TETRAHYDROISOQUINOLINE DERIVATIVE; PACLITAXEL;

ADVANCED CANCER; AGE DISTRIBUTION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; COMBINATION CHEMOTHERAPY; DISTANT METASTASIS; HISTOGENESIS; HISTOPATHOLOGY; HUMAN; OFF LABEL DRUG USE; PRACTICE GUIDELINE; REVIEW; SOFT TISSUE SARCOMA; SYSTEMIC THERAPY; EVIDENCE BASED MEDICINE; PATHOLOGY; SARCOMA; TREATMENT OUTCOME; ARTHRALGIA; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL (TOPIC); EDEMA; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HISTOLOGY; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; RHABDOMYOLYSIS; SENSORY NEUROPATHY;

ANTINEOPLASTIC AGENTS; DIOXOLES; DOXORUBICIN; EVIDENCE-BASED MEDICINE; HUMANS; IFOSFAMIDE; PYRIMIDINES; SARCOMA; SULFONAMIDES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 84902256995     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000362631     Document Type: Review

References (38)

1. Fletcher CDM, et al. (eds): WHO classification of tumours of soft tissue and bone, 4th ed. Lyon, IARC Press, 2013.
2. Casali PG, Blay JY; ESMO/CONTICANET/ EUROBONET consensus panel of experts: Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v198-203.
3. Stiller CA, Trama A, Serraino D, et al.: Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. Eur J Cancer 2013;49: 684-695.
4. Eilber FC, Brennan MF, Eilber FR, et al.: Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 2004;101:2270-2275.
5. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: Analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:739-747.
6. Judson I, Verweij J, Gelderblom H, et al.: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol 2014; 15:415-423.
7. Issels RD, Lindner LH, Verweij J, et al.: Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol 2010;11:561-570.
8. Tierney JF, Mosseri V, Stewart LA, et al.: Adjuvant chemotherapy for soft-tissue sarcoma: Review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469-475.
9. Pervaiz N, Colterjohn N, Farrokhyar F, et al.: A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;13:573-581.
10. Karavasilis V, Seddon BM, Ashley S, et al.: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retro-spective analysis and identification of prognostic factors in 488 patients. Cancer 2008;112:1585-1591.
11. Grimer R, Judson I, Peake D, Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma 2010;2010:506182.
12. Santoro A, Tursz T, Mouridsen H, et al.: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545.
13. Kim S, Ott HC, Wright CD, et al.: Pulmonary resection of metastatic sarcoma: Prognostic factors associated with improved outcomes. Ann Thorac Surg 2011;92:1780-1786.
14. Pautier P, Floquet A, Penel N, et al.: Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 2012;17:1213-1220.
15. Bramwell V, Blackstein M, Belanger K, et al.: A phase II study of docetaxel in chemotherapynaïve patients with recurrent or metastatic adult soft tissue sarcoma. Sarcoma 1998;2:29-33.
16. Schlemmer M, Reichardt P, Verweij J, et al.: Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008;44:2433-2436.
17. Riggs CE: Antitumor antibiotics; in Perry MC (ed.): The chemotherapy sourcebook. Lippincott Williams and Wilkins, 2001, pp. 231-234.
18. Lorigan P, Verweij J, Papai Z, et al.: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:3144-3150.
19. Hensley M, Hagerty K, Kewalramani T, et al.: American Society of Clinical Oncology 2008 cliniretrocal practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2008;27:127-145.
20. Van Oosterom AT, Mouridsen HT, Nielsen OS, et al.: Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002;38:2397-2406.
21. Blay JY, Sleijfer S, Schöffski P, et al.: International expert opinion on patient-tailored management of soft tissue sarcomas. Eur J Cancer 2014;50:679-689.
22. Schöffski P, Dumez H, Wolter P, et al.: Clinical impact of trabectedin (ecteinascidin-743) in advanced/ metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008;9:1609-1618.
23. Schöffski P, Cerbone L, Wolter P, et al.: Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: An effective and patient-friendly palliative treatment option. Onkologie 2012;35:14-17.
24. Schöffski P, Taron M, Jimeno J, et al.: Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. Eur J Cancer. 2011;47:1006-1012.
25. Dileo O, Sanfilippo R, Grosso F, et al.: Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions. 2010 ASCO Annual Meeting Abstracts. J Clin Oncol 2010;28: No. 7S (abstract 10030).
26. Demetri GD, Chawla SP, Von Mehren M, et al.: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27: 4188-4196.
27. Maki RG, Wathen JK, Patel SR, et al.: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:2755-2763. Erratum in: J Clin Oncol 2007;25:3790.
28. Garcia-del-Muro X, López-Pousa A, Maurel J, et al.: Randomized phase II study comparing gemcitabine plus dacarbazine alone in patients with previously treated soft tissue sarcoma: A Spanish Group for Research on Sarcomas Study. J Clin Oncol 2011;29:2528-2533.
29. Grochow LB: Covalent DNA-binding drugs; in Perry MC (ed.): The chemotherapy sourcebook. Lippincott Williams and Wilkins, 2001, pp. 196-197.
30. Schöffski P, Wolter P, Clement P, et al.: Trabectedin (ET-743): Evaluation of its use in advanced softtissue sarcoma. Future Oncol 2007;3:381-392.
31. Jones B, Komarnitsky P, Miller GT, et al.: Anticancer activity of stabilized palifosfamide in vivo: Schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs 2012;23:173-184.
32. Liu Q, Sun JD, Wang J, Ahluwalia D, et al.: TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: Optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012;69:1487-1498.
33. Ryan CW, Schöffski P, Merimsky O, et al.: A phase 3 multicenter, international, randomized, doubleblind, placebo-controlled study of doxorubicin plus palifosfamide vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma. ECCO Congress 2013, Amsterdam.
34. Schöffski P, Ray-Coquard IL, Cioffi A, et al.: Activity of eribulin mesylate in patients with soft-tissue sarcoma: A phase 2 study in four independent histological subtypes. Lancet Oncol 2011;12:1045-1052.
35. Hurwitz HI, Dowlati A, Saini S, et al.: Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-4227.
36. Sleijfer S, Ray-Coquard I, Papai Z, et al.: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009;27:3126-3132.
37. Van der Graaf WT, Blay JY, Chawla SP, et al.: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379: 1879-1886.
38. The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 (Suppl 7):vii92-99.